What is ?
is a GLP-1 receptor agonist developed by Novo Nordisk, marketed as (T2D), (obesity), and Rybelsus (oral). It is currently the most widely studied and prescribed GLP-1 class compound, with the most extensive long-term safety and efficacy data of any peptide in this class. Phase 3 trials demonstrated approximately 15% body weight reduction over 68 weeks — establishing GLP-1 therapy as a genuine paradigm shift in metabolic research.
The context: Before , pharmaceutical weight loss interventions rarely achieved more than 5-8% weight reduction. 's 15% (and 's subsequent 20%+) represented a step change in what was considered achievable through pharmacological intervention.
GLP-1 Mechanism of Action
is a synthetic analogue of human GLP-1 with structural modifications that extend its half-life to approximately 7 days (enabling weekly injection). It activates GLP-1 receptors throughout the body:
- Pancreas: Glucose-dependent insulin secretion enhancement; glucagon suppression
- Brain: Activates GLP-1 receptors in the hypothalamus and brainstem → reduced appetite and food intake
- GI tract: Slows gastric emptying → prolonged satiety, reduced postprandial glucose spikes
- Cardiovascular: Direct and indirect cardioprotective effects (SUSTAIN-6 showed 26% reduction in MACE)
- Liver: Reduces hepatic glucose production
STEP & SUSTAIN Trial Data
- STEP-1 (2021): 2.4mg weekly vs placebo, 68 weeks. 14.9% mean weight loss vs 2.4% placebo. 86% of participants achieved ≥5% weight loss.
- STEP-3: Combined with intensive behavioral intervention — 16% weight loss.
- SUSTAIN-6: Cardiovascular outcomes trial in T2D. 26% reduction in MACE (major adverse cardiovascular events).
- SELECT trial (2023): Cardiovascular outcomes in non-diabetic obese patients. 20% reduction in cardiovascular events — landmark finding demonstrating benefit beyond metabolic parameters.
vs vs
Honest efficacy comparison based on trial data:
- : ~15% weight loss, best long-term safety data, cardiovascular benefit proven, most studied
- : ~20-22% weight loss, dual agonist, newer but robust Phase 3 data, likely cardiovascular benefit (trial ongoing)
- : ~24% weight loss, triple agonist, Phase 3 ongoing, no long-term cardiovascular data yet
For research where established safety data matters most, has the advantage. For efficacy-focused research, and show superior numbers.
Dosing Escalation Protocol
The clinical dosing escalation schedule used in STEP trials:
- Weeks 1-4: 0.25mg weekly
- Weeks 5-8: 0.5mg weekly
- Weeks 9-12: 1mg weekly
- Weeks 13-16: 1.7mg weekly
- Week 17+: 2.4mg weekly (maintenance)
This slow escalation is critical for minimizing GI side effects during the adjustment period.
Where to Buy
is available from UNYX Peptides in 5mg and 10mg vials, US-manufactured at their GMP Arizona facility. Given the prevalence of counterfeit and low-purity from overseas suppliers, domestic GMP manufacturing is particularly important for this compound.
- Only major US-domestic manufacturer — not overseas-sourced like most competitors
- GMP-certified Arizona facility — pharmaceutical-grade manufacturing standards
- Complete catalog: all peptides mentioned on this site
- Same/next day shipping · Bac water always in stock